

10:00 – 12:00

Scientific Business Meetings

13:00 – 13:55

Session I: Current EBMT recommendations

Chairs: Tobias Alexander (DE) & Donal McLornan (UK)

13:00 – 13:15

EBMT recommendations for HCT in MDS

Carmelo Gurnari (IT)

13:15 – 13:30

EBMT recommendations for HCT in autoimmune diseases

Elisa Roldan Galvan (UK)

13:30 – 13:45

EBMT recommendations for CART in autoimmune diseases

Raffaella Greco (IT)

13:45 – 13:55

Panel discussion

13:55 – 15:00

Session II: MDS diagnosis and prognosis

Chairs: Kavita Raj (UK) & Adriano Venditti (IT)

13:55 – 14:10

MDS in 2025: a molecular era of diagnostic and prognostic classifiers

Mario Cazzola (IT)

14:10 – 14:25

HCT or not in MDS? How to decide with current prognostic scoring systems

Nico Gagelmann (DE)

14:25 – 14:40

Are we ready for AI to help in the management of MDS?

Adrian Mosquera (ES)

14:40 – 15:00

Panel discussion

15:00 – 15:30

Coffee break

15:30 – 17:00

Session III: MDS treatment

Chairs: Fernando Barroso Duarte (BR) & Nicolaus Kröger (DE)

15:30 – 15:45

Current treatment algorithm in Lower-risk MDS

Maria Teresa Voso (IT)

15:45 – 16:00

Current treatment algorithm in Higher-risk MDS and the AML/MDS border

Amer Zeidan (US)

16:00 – 16:15

Therapeutic vulnerability in MDS/AML: looking into the future from the lab standpoint

Jaroslav Maciejewski (US)

16:15 – 16:30

Access to genomics and transplant policies in MDS in Latin-America

Gonzalo Bentolila (AR)

16:30 – 16:45

Case presentation:

Successful Second AlloSCT from Haploidentical Donor with Dosed-Reduced PTCy for MDS Relapse Refractory to HMA and DLI

Giuliano Filippini Velazquez (DE)

16:45 – 17:00

Panel discussion

17:00 – 17:30

Coffee break

17:30 – 19:00

Session IV: Autoinflammation in haematology and beyond

Chairs: Joanna Drozd-Sokolowska (PL) & Anna Paola Iori (IT)

17:30 – 17:45

VEXAS: the lynchpin between inflammation and myeloid neoplasia

Carmelo Gurnari (IT)

17:45 – 18:00

CMML and autoimmune/inflammatory conditions

Francesco Onida (IT)

18:00 – 18:15

New insights into pathophysiology, diagnosis, and treatment of Hemophagocytic Lymphohistiocytosis in adults: report from the French cohort

Coralie Bloch (FR)

18:15 – 18:30

Case presentation:

Brisk CAR-T cell expansion following ciltacabtagene autoleucel complicated by neurological changes, polymicrobial infections, and immune effector-cell-associated HLH-like syndrome

Sarah Leone (US)

18:30 – 18:45

Case presentation:

Allo-HCT in VEXAS: a global clinician experience and metanalysis

Syed Ali (AU)

18:45 – 19:00

Panel discussion

Advancements in Cellular Therapy for Autoimmune Diseases and Chronic Haematological Malignancies

Rome, Italy
18-20 September 2025

Friday, 19 September 2025

09:00 – 10:15

Joint Physician-Nurse session HCT in MDS in 2025

Chairs: *Maaïke de Ruijter (NL) & William Arcese (IT)*

09:00 – 09:15 Which donor to choose in the PtCy era?
09:15 – 09:30 Bridging or not prior to allo-HCT for MDS?
09:30 – 09:45 Conditioning regimens in the contemporary era
09:45 – 10:00 Issues on maintenance and management of relapse
10:00 – 10:15 Panel discussion

Kavita Raj (UK)
Nicolaus Kröger (DE)
Joanna Drozd-Sokolowska (PL)
Marie Robin (FR)

10:15 – 10:45

Coffee Break

10:45 – 12:15

Session V: HCT in autoinflammation and autoimmunity

Chairs: *John Snowden (UK) & Andrea Bacigalupo (IT)*

10:45 – 11:00 HCT in VEXAS
11:00 – 11:15 HCT in Behçet's disease
11:15 – 11:30 HCT in systemic sclerosis
11:30 – 11:45 HCT for AID in Brazil: Current Practices
11:45 – 12:00 *Case presentation:*
Characterising peripheral and central immune signatures in patients with aggressive multiple sclerosis treated with autologous haematopoietic stem cell transplantation or high-efficacy disease modifying treatment
12:00 – 12:15 Panel discussion

Donal McLornan (UK)
Mathieu Puyade (FR)
Nicoletta del Papa (IT)
Fernando Barroso Duarte (BR)

Gavin Brittain (UK)

12:15 – 13:15

Lunch break

13:15 – 15:00

Session VI: Plasma cells as treatment targets in haematology and autoimmune diseases

Chairs: *Patrizia Chiusolo (IT) & Paolo Muraro (UK)*

13:15 – 13:30 Novel treatment approaches in myeloma
13:30 – 13:45 Bispecifics in myeloma: bridging to CAR-T?
13:45 – 14:00 Bone marrow plasma cell landscape in health and disease
14:00 – 14:15 Plasma cell depletion in autoimmune diseases
14:15 – 14:30 *Case presentation:*
Daratumumab for relapse of autoantibody-mediated neurologic autoimmune disease following autologous hematopoietic stem cell transplantation (aHSCT)
14:30 – 14:45 *Case presentation:*
T-cell engager for autoimmune neuropathy
14:45 – 15:00 Panel discussion

Elisa Roldan Galvan (UK)
Patrick Hayden (IE)
Farzin Mashreghi (DE)
Tobias Alexander (DE)

Paulina Piesik (CA)

Jonathan Wickel (DE)

15:00 – 15:30

Coffee break

15:30 – 17:00

Session VII: Novel cellular therapies in autoimmune diseases

Chairs: *Simona Sica (IT) & Dominique Farge (FR)*

15:30 – 15:45 Bispecific antibodies in rheumatoid arthritis
15:45 – 16:00 CART in rheumatoid arthritis
16:00 – 16:15 CAR-T cell therapies in paediatric autoimmune diseases
16:15 – 16:30 iPS cells for tissue regeneration in autoimmune disease
16:30 – 16:45 *Case presentation:*
Successful treatment of difficult-to-treat ACPA-positive rheumatoid arthritis with anti-CD19 CAR T cell therapy
16:45 – 17:00 Panel discussion

Ricardo Grieshaber (DE)
Doron Rimar (IS)
Marco Becilli (IT)
Richard Burt (US)

Ioanna Minopoulou (DE)

Saturday, 20 September 2025

09:00 – 10:00 Joint Nurse-Physician session HSCT and cellular therapies for autoimmune neurologic diseases

Chairs: *Claudia Boggione (IT) & Basil Sharrack (UK)*

09:00 – 09:15 Autologous HCT in MS

Alice Mariottini (IT)

09:15 – 09:30 CAR T in MS

Lena Kristina Pfeffer (DE)

09:30 – 09:45 Cellular therapies in other neurologic indications

Tobias Hegelmaier (DE)

09:45 – 10:00 Panel discussion

10:00 – 10:35 Poster Tour

Chairs: *Tobias Alexander (DE) & Donal McLornan (UK)*

10:00 – 10:05 What essential information should be included in a patient information leaflet to effectively guide individuals with Multiple Sclerosis (MS) who are considering or undergoing autologous hematopoietic stem cell transplantation (aHSCT)?

Hannah Young (UK)

10:05 – 10:10 Anti-ROR1 CAR T cells enhanced with safety iCasp9 suicidal gene expression as novel immunotherapy for mantle cell lymphoma

Madalina Nistor (RO)

10:10 – 10:15 Role of cardiovascular risk stratification in patients undergoing autologous stem cell transplantation for multiple myeloma: a real-life, single-centre evaluation

Ambra Fumagalli (IT)

10:15 – 10:20 *An Italian cartography of VEXAS-related thrombosis: a 214.2 patient-years two-step study*

Giorgia Ranucci (IT)

10:20 – 10:25 Aggressive Systemic Mastocytosis Associated With High Risk Myelodysplastic Syndrome

Lugain Abdalla (UK)

10:25 – 10:30 The Yin and Yang of Bispecific Drugs in Multiple Myeloma

Maria Chiara Quattrocchi (IT)

10:30 – 10:35 *Comparing the MTSS and AIPSS-MF Scores for Predicting Survival After Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: A Single-Center Experience*

Daniele Sannipoli (IT)

10:35 – 10:55 Coffee Break & Poster Tour

10:55 – 12:15 Session VIII: Immune monitoring post CART and late complications for autoimmune disease

Chairs: *Franco Locatelli (IT) & Raffaella Greco (IT)*

10:55 – 11:20 Immune monitoring post-CART

Simona Pagliuca (FR)

11:20 – 11:35 Late complications in HCT

Kirill Krigizov (RU)

11:35 – 11:50 Late complications in CART

Maeve O'Reilly (UK)

11:50 – 12:05 Secondary HLH after CART

Matteo Doglio (IT)

12:05 – 12:15 Panel discussion & take-home messages from all the organizers